Y0000773

Lansoprazole

Name: Lansoprazole
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₆H₁₄F₃N₃O₂S

CAS Number:

103577-45-3

Molecular Weight:

369.36

NACRES:

NA.24

PubChem Substance ID:

329831143

UNSPSC Code:

41116107

MDL number:

MFCD00866873

Product Name

Lansoprazole, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

SMILES string

Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F

InChI key

MJIHNNLFOKEZEW-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

lansoprazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... ATP4A(495), ATP4B(496)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Chemistry

Analytical Reference Materials for Pharma QC

Pharmacopeia & Metrological Institute Standards

Reference Materials

Application

Lansoprazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity.

Hiroshi Satoh

Current pharmaceutical design, 19(1), 67-75 (2012-09-07)

The proton pump inhibitors (PPIs) lansoprazole (LPZ) and omeprazole (OPZ) have been widely used for more than 20 years in the treatment of acid-related diseases such as gastro-duodenal ulcers and reflux esophagitis. Both LPZ and OPZ are derivatives of 2-[(2-

In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine.

Yun Jeong Lim et al.

Digestion, 86(2), 171-177 (2012-08-22)

Proton pump inhibitors (PPIs) are widely used to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcers. NSAIDs produce small intestinal injury and some PPIs have been reported to protect against NSAID-induced small bowel injury in rats. The aim of this study

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

Jyh-Ming Liou et al.

Lancet (London, England), 381(9862), 205-213 (2012-11-20)

Whether sequential treatment can replace triple therapy as the standard treatment for Helicobacter pylori infection is unknown. We compared the efficacy of sequential treatment for 10 days and 14 days with triple therapy for 14 days in first-line treatment. For

The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

D A Peura et al.

Alimentary pharmacology & therapeutics, 37(8), 810-818 (2013-03-05)

Higher body mass index (BMI) is a recognised risk factor for gastro-oesophageal reflux disease (GERD). Data regarding the impact of BMI on proton pump inhibitor (PPI) therapy are conflicting. To assess the impact of BMI on baseline heartburn symptom severity

Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.

Jun-Won Chung et al.

Journal of gastroenterology and hepatology, 27(11), 1675-1680 (2012-08-02)

Increased resistance of Helicobacter pylori to antibiotics has increased the need to develop new first-line treatments for H. pylori. We have prospectively evaluated 10-day sequential versus conventional triple therapy in peptic ulcer patients. One hundred and fifty-nine patients with peptic ulcer

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service